Luis I Sanchez-Abarca
Overview
Explore the profile of Luis I Sanchez-Abarca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Guerrero E, Sanchez-Abarca L, Domingo E, Ramos T, Bejarano-Garcia J, Gonzalez-Campos J, et al.
Front Immunol
. 2018 Sep;
9:1971.
PMID: 30233577
The relevance of the immune system in cancer has long been studied. Autologous adoptive T cell therapies, based on the use of tumor infiltrating lymphocytes (TILs), have made great progress...
2.
Macias R, Sanchez-Martin A, Rodriguez-Macias G, Sanchez-Abarca L, Lozano E, Herraez E, et al.
Oncotarget
. 2018 Jul;
9(47):28474-28485.
PMID: 29983874
Background: Chemoresistance often limits the success of the pharmacological treatment in acute myeloid leukemia (AML) patients. Although positive results have been obtained with tyrosine kinase inhibitors (TKIs), such as sorafenib,...
3.
Preciado S, Muntion S, Rico A, Perez-Romasanta L, Ramos T, Ortega R, et al.
Biol Blood Marrow Transplant
. 2017 Nov;
24(3):443-451.
PMID: 29155314
Bone marrow mesenchymal stromal cells (MSCs) are precursors of adipocytes and osteoblasts and key regulators of hematopoiesis. Irradiation is widely used in conditioning regimens. Although MSCs are radio-resistant, the effects...
4.
Caballero-Velazquez T, Montero I, Sanchez-Guijo F, Parody R, Saldana R, Valcarcel D, et al.
Clin Cancer Res
. 2016 Jul;
22(23):5673-5681.
PMID: 27358490
Purpose: We describe the results of a prospective multicenter phase I/II trial evaluating the impact of the use of vitamin D (VitD) from day -5 to +100 on the outcome...
5.
Baez A, Piruat J, Caballero-Velazquez T, Sanchez-Abarca L, Alvarez-Laderas I, Barbado M, et al.
Am J Cancer Res
. 2015 Jan;
5(1):386-95.
PMID: 25628947
Memory B cells (MBCs) remain in a quiescent state for years, expressing pro-survival and anti-apoptotic factors while repressing cell proliferation and activation genes. During their differentiation into plasma cells (PCs),...
6.
Sanchez-Abarca L, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, et al.
Blood
. 2009 Nov;
115(1):107-21.
PMID: 19887673
Cytokine genes are targets of multiple epigenetic mechanisms in T lymphocytes. 5-azacytidine (5-azaC) is a nucleoside-based DNA methyltransferase inhibitor that induces demethylation and gene reactivation. In the current study, we...
7.
Blanco B, Perez-Simon J, Sanchez-Abarca L, Caballero-Velazquez T, Gutierrez-Cossio S, Hernandez-Campo P, et al.
Haematologica
. 2009 Jun;
94(7):975-83.
PMID: 19508976
Background: In vitro depletion of alloreactive T cells using the proteasome inhibitor bortezomib is a promising approach to prevent graft-versus-host disease after allogeneic stem cell transplantation. We have previously described...
8.
Tabera S, Perez-Simon J, Diez-Campelo M, Sanchez-Abarca L, Blanco B, Lopez A, et al.
Haematologica
. 2008 Jul;
93(9):1301-9.
PMID: 18641017
Background: Mesenchymal stem cells are multilineage non-hematopoietic progenitor cells that play a key role in supporting the lymphohematopoietic system. Their distribution in bone marrow and secondary lymphoid organs allows an...
9.
Bougie D, Benito A, Sanchez-Abarca L, Torres R, Birenbaum J, Aster R
Blood
. 2007 Apr;
109(8):3608-9.
PMID: 17409346
No abstract available.
10.
Blanco B, Perez-Simon J, Sanchez-Abarca L, Carvajal-Vergara X, Mateos J, Vidriales B, et al.
Blood
. 2005 Nov;
107(9):3575-83.
PMID: 16282346
We explored the ability of the proteasome inhibitor bortezomib, which prevents nuclear factor kappaB (NF-kappaB) activation, to block T-cell activation, proliferation, and survival within alloreactive compared with resting T cells....